The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss

References

• Joint Health Surveys Unit on behalf of the Department of Health. Health survey for England: cardiovascular disease 1998. London: The Stationery Office, 1999
   Google Scholar
• Storing up problems, the medical case for a slimmer nation. Report of a working party, Royal College of Physicians, Royal College of Paediatrics and Child Health, Faculty of Public Health. London: Royal College of Physicians, 2004
   Google Scholar
• Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998;22:39–47
   PubMed Web of Science ®Google Scholar
• National Audit Office. Tackling obesity in England. London: The Stationery Office, 2001
   Google Scholar
• Calle EE, Thun MJ. Obesity and cancer. Oncogene 2004;23: 6365–78
   PubMed Web of Science ®Google Scholar
• Arik TH, Desser KB, Benchimol A. Obesity and heart disease. Ariz Med 1985;42:12–3
   PubMedGoogle Scholar
• Shinton R, Sagar G, Beevers G. Body fat and stroke: unmasking the hazards of overweight and obesity. J Epidemiol Community Health 1995;49:259–64
   PubMed Web of Science ®Google Scholar
• Kim SH, Abbasi F, Reaven GM. Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 2004;27:1998–2002
   Google Scholar
• Boden G. Free fatty acids – the link between obesity and insulin resistance. Endocr Pract 2001;7:44–51
   PubMedGoogle Scholar
• Morgan CL, Currie CJ, Stott NC, et al. The prevalence of multiple diabetes-related complications. Diabet Med 2000;17:146–51
   PubMed Web of Science ®Google Scholar
• Astrup A, Finer N. Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus’? Obes Rev 2000; 1:57–9
   PubMedGoogle Scholar
• Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997;146:214–22
   Google Scholar
• Hickey ME, Hall TR. Insulin therapy and weight change in Native-American NIDDM patients. Diabetes Care 1993;16:364–8
   PubMed Web of Science ®Google Scholar
• Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S25–8
   PubMedGoogle Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med 344; 18: 1343–50
   Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12
   PubMed Web of Science ®Google Scholar
• Miller YD, Dunstan DW. The effectiveness of physical activity interventions for the treatment of overweight and obesity and type 2 diabetes. J Sci Med Sport 2004;7(Suppl 1):52–9
   PubMedGoogle Scholar
• Beebe CA, Pastors JG, Powers MA, Wylie-Rosett J. Nutrition management for individuals with noninsulin-dependent diabetes mellitus in the 1990s: a review by the Diabetes Care and Education dietetic practice group. J Am Diet Assoc 1991;91: 196–202
   Google Scholar
• Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21:S12–23
   PubMed Web of Science ®Google Scholar
• Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306–13
   PubMed Web of Science ®Google Scholar
• Sjöström L, Rissanen A, Anderson T, et al. Randomised placebocontrolled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167–73
   Google Scholar
• Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21:1288–94
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomised placebo-controlled trial. Diabetes Obes Metab 2002;4:415–423
   PubMed Web of Science ®Google Scholar
• Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1671
   Google Scholar
• Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002;25: 1033–41
   Google Scholar
• Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:321–6
   Google Scholar
• Kelley DE, Kuller LH, McKolanis TM, et al. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004;27:33–40
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics for Xenical. Available from http://www.emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=1746#INDICATIONS [Accessed 4 Aug 2005]
   Google Scholar
• National Institute for Clinical Excellence. Orlistat for treatment of obesity in adults. Available from http://www.nice.org.uk/page.aspx?o=15731 [Accessed 29 Sept 2005]
   Google Scholar
• National Formulary. Available from http://www.bnf.org [Last Accessed 28 September 2005]
   Google Scholar
• PRODIGY guidance – diabetes type 2 – blood glucose management. Available from http://www.prodigy.nhs.uk/guidance%20asp?gt%20=%20Diabetes%20-%20glycaemic%20control [Accessed 28 Sept 2005]
   Google Scholar
• National Institute for Clinical Excellence. 2000/026 NICE issues guidance on rosiglitazone for type 2 diabetes. Available from http://www.nice.org.uk/page.aspx?o=38020 [Accessed 1 July 2005]
   Google Scholar
• Ballinger A. Orlistat in the treatment of obesity. Expert Opin Pharmacother 2000;4:841–7
   Google Scholar